About The Study: In this secondary analysis of a randomized clinical trial, patients who received at least one COVID-19 vaccine dose after acute coronary syndromes had similar rates of the primary composite end point and major adverse cardiovascular events (MACE) compared with unvaccinated patients. However, retrospective studies have demonstrated a short-term reduction in MACE risk after COVID-19 vaccination.
About The Study: In this secondary analysis of a randomized clinical trial, patients who received at least one COVID-19 vaccine dose after acute coronary syndromes had similar rates of the primary composite end point and major adverse cardiovascular events (MACE) compared with unvaccinated patients. However, retrospective studies have demonstrated a short-term reduction in MACE risk after COVID-19 vaccination.
Corresponding Author: To contact the corresponding author, Henrique Andrade R. Fonseca, Ph.D., email henrique.fonseca@einstein.br.
To access the embargoed study: Visit our For The Media website at this link
(doi:10.1001/jamanetworkopen.2024.13946)
Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.
# # #
Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time
About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication.
Journal
JAMA Network Open
